Myeloma UK has joined with other cancer charities to urge the Government to make progress on the licensing and regulation of medicines post Brexit. Along with Cancer Research UK and 17 other charities, Myeloma UK is helping to send a clear message to politicians that there must be no delay in access to life-saving cancer drugs after the UK leaves the European Union (EU).
The letter, which is addressed to Secretary of State for Health and Social Care, Jeremy Hunt, and Secretary of State for Business, Energy and Industrial Strategy, Greg Clark, calls for the Government to be clear about the UK’s future involvement with The European Medicines Agency (EMA) and cancer patient’s access to drugs.
The charities are also calling for clarification on clinical trials regulation as the EU Clinical Trials Regulation comes into effect in 2019 after the UK leaves the EU. This new regulation is set to streamline setting up clinical trials and will be vital in the progress of future cancer research.
Dr Simon Ridley, Director of Research, Myeloma UK said, “By signing this letter we hope to send a key message to the UK Government that we need clear answers as to how the future of cancer research and access to drugs will be affected when the UK leaves the EU.
“Myeloma UK is dedicated to keeping patients as the central focus of our work, and by working with other cancer charities and patient groups, we hope to protect the interests of myeloma patients.”
To read the full letter, please visit the Cancer Research UK website.